Janssen’s Stelara
(ustekinumab), an alternative
to tumour necrosis factor alpha
(TNF) inhibitors, was funded
in the Pharmaceutical Benefits
Scheme as a first and subsequent
line biological therapy for adult
patients with severe active psoriatic
arthritis, on 01 May this year.
Administered by subcutaneous
injection, the recommended dose
of ustekinumab for patients with
psoriatic arthritis is 45mg at week
0 and week 4, and then every 12
weeks thereafter.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Jun 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.